Epidemiology of sarcoidosis in northern Spain, 1999-2019: A population-based study

Fernández-Ramón, R.; Gaitán-Valdizán, J. J.; Sánchez-Bilbao, L.; Martín-Varillas, J. L.; Martínez-López, D.; Demetrio‐Pablo, Rosalía; González‐Vela, M. Carmen; Cifrián, José Manuel; Castañeda, Santos; Llorca, Javier; Blanco, Ricardo

doi:10.1016/j.ejim.2021.05.011

Cited by 7 publications

(6 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found a similar result concerning the age of the studied patients, with a mean age at diagnosis of around 53 years for females and 46 years for males, confirming previous data that a younger age of onset is characteristic of males. In our study, more than one-third of females (57 patients, 36%) were older than 60 years, confirming the results of Scandinavian, Japanese and Spanish studies [ 45 , 48 , 220 , 221 , 222 , 224 ]. This might be due, in our opinion, to an early asymptomatic disease or to a late diagnosis because of the worsening of symptoms and signs.…”

Section: Discussionsupporting

confidence: 92%

“…According to some studies, the disease is more frequent in young adults, but the first diagnosis is made later, usually in people with a mean age of approximately 50 years [ 1 , 3 , 13 , 59 , 96 , 223 , 224 , 225 , 226 , 227 ], confirming our data. In the ACCESS study (A Case-Control Etiologic Study of Sarcoidosis) the peak age was between 35 and 45 years [ 14 ], while in a UK survey it was found to be between 35 and 55 [ 78 ].…”

Section: Discussionsupporting

confidence: 90%

“…The review by Valeyre [ 20 ] shows that 70% of patients are diagnosed between 25 and 45 years old. It is remarkable to observe that age at diagnosis usually does not coincide with the onset, probably because of the asymptomatic course or the mimicking of symptoms and signs of other diseases, together with the usually accidental discovery of the disease by routine X-ray examination [ 224 ]. Musellim et al [ 223 ] identified a higher mean age at diagnosis for female patients compared to males, with a difference of 10 years between the two genders.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Sarcoid Uveitis: An Intriguing Challenger

Allegri¹,

Olivari²,

Rissotto

et al. 2022

Medicina

View full text Add to dashboard Cite

The purpose of our work is to describe the actual knowledge concerning etiopathogenesis, clinical manifestations, diagnostic procedures, complications and therapy of ocular sarcoidosis (OS). The study is based on a recent literature review and on the experience of our tertiary referral center. Data were retrospectively analyzed from the electronic medical records of 235 patients (461 eyes) suffering from a biopsy-proven ocular sarcoidosis. Middle-aged females presenting bilateral ocular involvement are mainly affected; eye involvement at onset is present in one-third of subjects. Uveitis subtype presentation ranges widely among different studies: panuveitis and multiple chorioretinal granulomas, retinal segmental vasculitis, intermediate uveitis and vitreitis, anterior uveitis with granulomatous mutton-fat keratic precipitates, iris nodules, and synechiae are the main ocular features. The most important complications are cataract, glaucoma, cystoid macular edema (CME), and epiretinal membrane. Therapy is based on the disease localization and the severity of systemic or ocular involvement. Local, intravitreal, or systemic steroids are the mainstay of treatment; refractory or partially responsive disease has to be treated with conventional and biologic immunosuppressants. In conclusion, we summarize the current knowledge and assessment of ophthalmological inflammatory manifestations (mainly uveitis) of OS, which permit an early diagnostic assay and a prompt treatment.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Sarcoid Uveitis: An Intriguing Challenger

Allegri¹,

Olivari²,

Rissotto

et al. 2022

Medicina

View full text Add to dashboard Cite

show abstract

“…In Canada, migrants accounted for 10% of cases, with South East Asian migrants disproportionately represented [7]. Higher incidence rates among women have been reported in some studies, [6,8,9] but not in others [10]. The pattern of disease may differ for women, and they may be diagnosed at a later age [1,11,12].…”

Section: Introductionmentioning

confidence: 99%

Diagnostic delay of sarcoidosis: Protocol for an integrated systematic review

et al. 2023

View full text Add to dashboard Cite

Introduction Sarcoidosis is a rare systemic inflammatory granulomatous disease of unknown cause. It can manifest in any organ. The incidence of sarcoidosis varies across countries, and by ethnicity and gender. Delays in the diagnosis of sarcoidosis can lead to extension of the disease and organ impairment. Diagnosis delay is attributed in part to the lack of a single diagnostic test or unified commonly used diagnostic criteria, and to the diversity of disease manifestations and symptom load. There is a paucity of evidence examining the determinants of diagnostic delay in sarcoidosis and the experiences of people with sarcoidosis related to delayed diagnosis. We aim to systematically review available evidence about diagnostic delay in sarcoidosis to elucidate the factors associated with diagnostic delay for this disease in different contexts and settings, and the consequences for people with sarcoidosis. Methods and analysis A systematic search of the literature will be conducted using PubMed/Medline, Scopus, and ProQuest databases, and sources of grey literature, up to 25th of May 2022, with no limitations on publication date. We will include all study types (qualitative, quantitative, and mixed methods) except review articles, examining diagnostic delay, incorrect diagnosis, missed diagnosis or slow diagnosis of all types of sarcoidosis across all age groups. We will also examine evidence of patients’ experiences associated with diagnostic delay. Only studies in English, German and Indonesian will be included. The outcomes we examine will be diagnostic delay time, patients’ experiences, and factors associated with diagnostic delay in sarcoidosis. Two people will independently screen the titles and abstracts of search results, and then the remaining full-text documents against the inclusion criteria. Disagreements will be resolved with a third reviewer until consensus is reached. Selected studies will be appraised using the Mixed Methods Appraisal Tool (MMAT). A meta-analysis and subgroup analyses of quantitative data will be conducted. Meta-aggregation methods will be used to analyse qualitative data. If there is insufficient data for these analyses, a narrative synthesis will be conducted. Discussion This review will provide systematic and integrated evidence on the diagnostic delay, associated factors, and experiences of diagnosis delay among people with all types of sarcoidosis. This knowledge may shed light on ways to improve diagnosis delays in diagnosis across different subpopulations, and with different disease presentations. Ethics and dissemination Ethical approval will not be required as no human recruitment or participation will be involved. Findings of the study will be disseminated through publications in peer-reviewed journals, conferences, and symposia. Trial registration PROSPERO Registration number: CRD42022307236. URL of the PROSPERO registration: https://www.crd.york.ac.uk/PROSPEROFILES/307236_PROTOCOL_20220127.pdf.

show abstract

“…Sarcoidosis is a rare systemic inflammatory granulomatous disease of unknown cause with broad manifestation ranging from acute epileptic seizures to subtle symptoms such as fatigue and pain; syndromes that are subject to the organ involved (1-3). Sarcoidosis can manifest in any organ including the lungs, skin, liver, joints, nervous system, and eyes (4, 5), but it most commonly affects the lungs, referred to as pulmonary sarcoidosis (PS) (6). There is no single diagnostic test for sarcoidosis or a unified, commonly used diagnostic criteria.…”

Section: Introductionmentioning

confidence: 99%

Diagnostic delay of sarcoidosis: protocol for an integrated systematic review

Namsrai

Desborough

Gregory

et al. 2022

Preprint

View full text Add to dashboard Cite

Sarcoidosis is a rare systemic inflammatory granulomatous disease with broad manifestation ranging from acute epileptic seizures to fatigue and pain syndromes that are subject to the organ involved. Delays in the diagnosis of sarcoidosis are attributed to the lack of a single diagnostic test or unified commonly used diagnostic criteria, and diagnosis based on exclusion of possible alternative diagnoses. We aim to systematically review the evidence about diagnostic delay in sarcoidosis to elucidate the causes and consequences of diagnostic delay, including people with sarcoidosis’ experiences. This will inform the development of interventions, tools, and health policies aiming to improve diagnostic efficiency and patients’ experiences of sarcoidosis.

show abstract

Epidemiology of sarcoidosis in northern Spain, 1999-2019: A population-based study

Cited by 7 publications

References 35 publications

Sarcoid Uveitis: An Intriguing Challenger

Sarcoid Uveitis: An Intriguing Challenger

Diagnostic delay of sarcoidosis: Protocol for an integrated systematic review

Diagnostic delay of sarcoidosis: protocol for an integrated systematic review

Contact Info

Product

Resources

About